Shanghai ZhenGe Completes $100 Million Round for Biologic CDMO Services

Shanghai ZhenGe Biotech completed a $100 million C Round to strengthen its biologic drug CDMO services. The company offers end-to-end services from concept to commercialization to help customers discover, develop and manufacture biologics. Founded in 2017, ZhenGe has worked with more than 100 biopharma and biotech customers, completing over 150 projects that range from cell line development projects to IND applications and clinical trial production. ZhenGe has expertise with monoclonal and bispecific antibodies, ADCs, fusion proteins and vaccines. The C Round was led by Goldman Sachs Asset Management and Sofina. More details.... Share this with colleagues: // //